Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.

Julie E Bauman Nabil F SabaDenise RoeJessica R BaumanJohn KaczmarAarti BhatiaJameel MuzaffarRicklie JulianSteven WangShethal BearellyAudrey BakerConor E Steuer Anshu Giri Barbara A BurtnessSara CentuoriCarlos CaulinRobert KleinKathylynn SabodaStefanie ObaraChristine H Chung

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

The ficlatuzumab-cetuximab arm met significance criteria for PFS and warrants phase III development. HPV-negative HNSCC merits consideration as a selection criterion.

Keyphrases

phase iii
open label
placebo controlled
metastatic colorectal cancer
double blind
clinical trial
phase ii
locally advanced
wild type
squamous cell carcinoma
small cell lung cancer
high grade
study protocol
tyrosine kinase
rectal cancer
radiation therapy
cervical cancer screening